<DOC>
	<DOCNO>NCT00928447</DOCNO>
	<brief_summary>The purpose study compare effect safety rHuPH20 placebo treatment skin allergic reaction nickel . The study drug placebo administer intradermal injection .</brief_summary>
	<brief_title>Study Intradermal Injection rHuPH20 Placebo Subjects With Nickel Allergic Contact Dermatitis</brief_title>
	<detailed_description>This pilot Phase II , prospective , double-blind , placebo-controlled study compare efficacy , safety tolerability rHuPH20 placebo control administer intradermally ( ID ) prevention treatment subject contact allergy nickel . This study involve two treatment regimen , run parallel ( Treatment Regimens 1 2 ) .</detailed_description>
	<mesh_term>Dermatitis</mesh_term>
	<mesh_term>Dermatitis , Contact</mesh_term>
	<mesh_term>Dermatitis , Allergic Contact</mesh_term>
	<mesh_term>Nickel</mesh_term>
	<criteria>Females 1860 year age . Females childbearing potential must use standard effective mean birth control duration study . Known contact dermatitis nickel confirm positive patchtest result nickel sulfate . Intact normal skin without potentially obscure tattoo , acne , dermatitis , pigmentation lesion posterior aspect torso ( back ) area intend allergen test dose administration . Vital sign ( BP , HR , temperature , respiratory rate ) within normal range , range , assess Investigator clinically significant mutually agree Investigator Sponsor Medical Monitor subject need exclude study reason . A negative serum urine pregnancy test ( female childbearing potential ) within 14 day initial study drug administration . Subject good general health base medical history physical examination , without medical condition might prevent completion study drug injection assessment require protocol . Decisionmaking capacity willingness ability comply requirement full completion study . Signed , write Institutional Review Board ( IRB ) /ECapproved informed consent . Nickel allergen patch test great ++ reaction . Subjects treat chemotherapy agent systemic corticosteroid within past 3 month . Use topical steroid , antihistamine , immunosuppressant use near site allergen testing/injection within 14 day . Use oral antihistamine within 14 day study conduct . Extensive ongoing outbreak contact dermatitis anywhere body . Pregnant woman breastfeed . Subjects current disease state affect immune response ( e.g. , flu , cancer , HIV ) . Known allergy hyaluronidase ingredient dose preparation . History autoimmune disorder . Subjects medical condition , opinion investigator , might significantly affect ability safely participate study affect conduct study . Examples might include asthma , diabetes , heart disease , epilepsy , cancer , etc .</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>60 Years</maximum_age>
	<verification_date>September 2012</verification_date>
	<keyword>rHuPH20</keyword>
	<keyword>Recombinant Human hyaluronidase</keyword>
</DOC>